HealthEZ Launches EZrx: Redefining Pharmacy Benefits Management
MINNEAPOLIS--(BUSINESS WIRE)--HealthEZ, a national third-party benefits administrator, is proud to introduce EZrx, a next-generation pharmacy solution that leverages six cost-reduction strategies to deliver up to 50% savings compared to traditional pharmacy benefit plans. This solution supports self-funded plans by targeting high-cost prescriptions and optimizing pharmacy spend.
EZrx is designed to bring down pharmacy costs by up to 50% compared to traditional PBM solutions.
Share
EZrx places the clinical review outside of the Pharmacy Benefit Manager, ensuring employers pay the lowest net cost on any medication over $1,000 per fill. This program will soon feature an innovative digital experience, allowing members to compare prices and transfer their prescriptions to the lowest-cost pharmacy with the click of a button.
By shifting control of clinical review away from the PBM, EZrx significantly reduces costs by identifying and sourcing medications through the most effective channels while simplifying everything from patient assistance to authorization management. EZrx is a game changer for employers looking to control rising pharmacy costs while ensuring exceptional care for their employees.
According to Josh Schreiner, Chief Product Officer at HealthEZ, ' EZrx is designed to bring down pharmacy costs by up to 50% compared to traditional PBM solutions. By managing claims over $1,000, EZrx can identify the lowest net cost channel or alternative medication that can yield maximum savings for our customers while delivering a member incentive to produce a win-win for all parties involved.'
Learn more about how EZrx can revolutionize your pharmacy benefits at healthez.com/EZrx.
About HealthEZ
HealthEZ is a national third-party administrator helping employers across the U.S. design custom benefit plans that deliver better, more flexible coverage at lower costs. With a fully integrated model and robust digital platform, HealthEZ ensures a seamless experience for members while driving meaningful cost containment. Backed by a dedicated care advocacy team and expert guidance, HealthEZ simplifies self-funding—making it smarter, more efficient, and more effective for employers and their employees.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
33 minutes ago
- Business Wire
Deadline Approaching: Fortrea Holdings Inc. (FTRE) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 1, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Fortrea Holdings Inc. ('Fortrea' or the 'Company') (NASDAQ: FTRE) securities between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FORTREA HOLDINGS INC. (FTRE), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On September 25, 2024, the investment bank Jefferies downgraded Fortrea from buy to hold, citing perceived weaknesses in the Company's business model as a contract research organization ('CRO') amid pressure on biotechnology funding and that the cost savings Fortrea expects to achieve by existing transition services agreements ('TSAs') are 'not as material as one might think.' On this news, Fortrea's stock price fell $2.73, or 12.3%, to close at $19.48 per share on September 25, 2024, thereby injuring investors. Then, on December 6, 2024, Baird Equity Research stated that '[g]iven our ongoing concerns around the sector, [Fortrea's] choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell)[.]' On this news, Fortrea's stock price fell $1.90, or 8.1%, to close at $21.67 per share on December 6, 2024. Then, on March 3, 2025, before the market opened, Fortrea announced financial results for the fourth quarter and full year 2024, revealing the Company had missed its previously announced guidance for revenue and adjusted EBITDA for the full year 2024. The Company's financial results revealed full year adjusted EBITDA of $202.5 million, well below the Company's previously announced guidance of $220 million to $240 million. The Company also revealed full year revenue of $2.696 billion, which missed previously announced guidance of $2.7 billion to $2.725 billion. The Company further revealed financial guidance for the full year 2025, which projected declines in revenue and adjusted EBITDA, with revenues of $2.450 billion to $2.550 billion and adjusted EBITDA in the range of $170 million to $200 million. Thomas Pike ('Pike'), the Company's then-Chief Executive Officer ('CEO'), explained that 'full-service work for projects from the pre-spin period,' 'have less revenue and less profitability' and 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' Pike further revealed 'this older versus newer mix issue will continue to negatively impact our financial performance during 2025.' On this news, Fortrea shares fell $3.47, or 25.1%, to close at $10.38 per share on March 3, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Fortrea securities during the Class Period, you may move the Court no later than August 1, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
an hour ago
- Business Wire
Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. ('Organon' or the 'Company') (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR ORGANON INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company's dividend payout, from $0.28 to $0.02 and would 'redirect those funds to debt reduction.' On this news, Organon's stock price fell $3.48, or 26.9%, to close at $9.45 per share on May 1, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Organon's optimistic reports of the dividend payout as the Company's 'number one priority,' were offset by Organon's newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; (2) Organon planned to prioritize debt reduction following the Company's acquisition of Dermavant; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Organon securities during the Class Period, you may move the Court no later than July 22, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
an hour ago
- Business Wire
Deadline Alert: Red Cat Holdings, Inc. (RCAT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Red Cat Holdings, Inc. ('Red Cat' or the 'Company') (NASDAQ: RCAT) securities between , inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR RED CAT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? In March 2022, Red Cat announced that its subsidiary Teal Drones, Inc. ('Teal') had been selected to compete in Tranche 2 of the U.S. Army's Short Range Reconnaissance Program of Record (the 'SRR Program'). On July 27, 2023, Red Cat released its fiscal year 2023 financial results and revealed that its Salt Lake City Facility could only produce 100 drones per month and that construction of the facility was only 'substantially completed' and, while it could potentially reach a production capacity of one thousand drones per month over the next two to three years, it would require additional capital investments. On this news, Red Cat's stock price fell $0.10, or 8.9%, to close at $1.02 per share on July 28, 2023, thereby injuring investors. Then, on September 23, 2024, Red Cat released its first quarter fiscal 2025 financial results, missing consensus estimates and disclosing that it had spent 'the past four months . . . retooling [the Salt Lake City Facility] and preparing for high volume production[,]' while admitting that a 'pause in manufacturing of Teal 2 and building our Army prototypes impacted Teal 2 sales' because it 'couldn't produce and sell Teal 2 units while retooling [its] factory.' On this news, Red Cat's stock price fell $0.80, or 25.3%, over two consecutive trading days to close at $2.36 per share on September 25, 2024. Then, on November 19, 2024, Red Cat announced that it had won the SRR contract, stating that it was worth potentially hundreds of millions of dollars. However, on January 16, 2025, Kerrisdale Capital published a report alleging, among other things, that Red Cat had overstated that value of the SRR Contract and that it was worth approximately $20-25 million, based on U.S. Army budget documents. On this news, Red Cat's stock price fell $2.35, or 21.5%, over two consecutive trading days to close at $8.56 per share on January 17, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated; (2) the overall value of the SRR Contract was overstated; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Red Cat securities during the Class Period, you may move the Court no later than July 22, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
